Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Keryx Says Perifosine X-PECT Phase 3 Trial Failed To Meet Primary Goal

RELATED NEWS
Trade KERX now with 

Keryx Biopharmaceuticals, Inc. (KERX: Quote) said the Phase 3 "X-PECT", or Xeloda + Perifosine Evaluation in Colorectal cancer Treatment, clinical trial evaluating perifosine (KRX-0401) + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer failed to achieve the primary endpoint of improving overall survival versus capecitabine + placebo.

The company noted that 468 patients at sixty-five U.S. sites participated in the study.

Ron Bentsur, Chief Executive Officer of Keryx, stated, "We are all extremely disappointed with the results of the study...We will evaluate whether our Phase 3 study of Perifosine in relapsed/refractory multiple myeloma will continue as planned.

With approximately $31 million in cash as of March 31, 2012, and a well-controlled burn rate, we plan to focus our resources on the pending completion of the Zerenex (ferric citrate) long-term Phase 3 study for end stage renal disease (ESRD) patients with hyperphosphatemia, expected in the fourth quarter of 2012, and the New Drug Application (NDA) filing for Zerenex which will hopefully follow shortly thereafter."

Click here to receive FREE breaking news email alerts for Keryx Biopharmaceuticals Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Citing extreme fluctuation of the ruble, Apple Inc. (AAPL) has reportedly discontinued its online sales of products in Russia. Despite efforts of the Russian central bank, the ruble has been spiraling downward, with oil prices plunging to historic levels. The ruble shed around 19 percent on Wednesday.... General Motors said it has halted the delivery of cars to dealerships in Russia as it strives to overcome the business risks stemming from the collapse of the ruble. The terrorists, in this case, have won. In an unprecedented move that may have far-reaching cultural and political effects, Sony Pictures has scrapped the release of "The Interview." The plot of the film, a comedy starring Seth Rogen and James Franco, revolves around a fictional assassination...
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.